An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
NCT ID: NCT00057239
Last Updated: 2010-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
546 participants
INTERVENTIONAL
2003-03-31
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radafaxine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Duration of current depressive episode 12 weeks - 24 months
* Patients can read and write at a level sufficient to provide a signed consent
* If female, patients must be practicing an acceptable method of birth control
Exclusion Criteria
* Patients have not responded to two or more adequate courses of antidepressant therapy
* Patients cannot be currently abusing illicit drugs or alcohol
* Patients are not currently receiving psychotherapy
* Patients have received electroconvulsive therapy within 6 months prior to screening
* Patients are pregnant or lactating
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
GSK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials, M.D.
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Newport Beach, California, United States
GSK Investigational Site
Farmington, Connecticut, United States
GSK Investigational Site
Largo, Florida, United States
GSK Investigational Site
Maitland, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Edwardsville, Illinois, United States
GSK Investigational Site
Glen Burnie, Maryland, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Clementon, New Jersey, United States
GSK Investigational Site
Kenilworth, New Jersey, United States
GSK Investigational Site
Lawrence, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Dayton, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Eugene, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Conshohocken, Pennsylvania, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Irving, Texas, United States
GSK Investigational Site
Woodstock, Vermont, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Brown Deer, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OHB20001
Identifier Type: -
Identifier Source: org_study_id